Lucas Boone
Psychiatry · Mobile, ALNPI 1134651102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 544 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,547 and has fallen 51.1% since, to $1,244 in 2025. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 544 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$767
- Neurocrine Biosciences, Inc.$617
- plus $2K from 9 others
What the payments were for
- Food & beverage$9,539100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 70 | $1,943 |
| AbbVie(2 entities) | 170 | $1,911 |
| Teva Pharmaceuticals USA, Inc. | 92 | $1,492 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $1,141 |
| Otsuka America Pharmaceutical, Inc. | 42 | $767 |
| Neurocrine Biosciences, Inc. | 21 | $617 |
| Johnson & Johnson | 32 | $571 |
| E.r. Squibb & Sons, L.L.C. | 25 | $410 |
| Lundbeck LLC | 13 | $219 |
| Vanda Pharmaceuticals Inc. | 8 | $209 |
| Axsome Therapeutics, Inc. | 4 | $100 |
| Indivior Inc. | 4 | $81 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Orexo US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,543 in reported general payments places this provider in the 90th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Mobile
- Mark HaygoodMobile$348K
- Bradley SadlerMobile$124K
- Michael MarshallMobile$59K
- Mary Cohen ColsonMobile$10K
- Bradley BrooksMobile$6K
- Sandra ParkerMobile$5K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.